Talk Bio

Can Intellia's lonvo-z Turn CRISPR Promise into HAE Practice?

Chiesi Group Acquires KalVista Pharmaceuticals for $1.9 Billion to Expand Rare Disease Portfolio

Intellia Therapeutics Advances In Vivo CRISPR Therapy Lonvo-z to FDA After Positive Phase 3 HAELO Trial Results

BioCryst Snaps Up Fellow Angioedema Player Astria for $700M

FDA Approves CSL's Andembry, Directly Competing With Takeda's Takhzyro in HAE

FDA Delays Decision on KalVista's HAE Drug Sebetralstat, Citing Heavy Workload